Enziva Tablet contains a combination of Pancreatin (170 mg) and Dimethicone (80 mg), formulated to aid digestive health by enhancing enzymatic activity and reducing gastrointestinal discomfort. Pancreatin is a mixture of digestive enzymes including amylase, lipase, and protease, which facilitate the breakdown of carbohydrates, fats, and proteins, thereby improving nutrient absorption in patients with pancreatic insufficiency or related digestive disorders. Dimethicone acts as an anti-foaming agent that helps alleviate symptoms of bloating, gas, and abdominal distension by reducing surface tension and promoting the coalescence of gas bubbles in the gastrointestinal tract. Enziva is indicated for use in conditions such as chronic pancreatitis, cystic fibrosis, post-pancreatectomy, and other disorders characterized by insufficient pancreatic enzyme secretion, as well as for symptomatic relief of flatulence and discomfort associated with excessive intestinal gas. The combination therapy ensures both improved digestion and symptomatic relief, enhancing patient comfort and nutritional status. Enziva should be administered as directed by a healthcare professional, with dosage adjusted according to the severity of enzyme deficiency and clinical response. Caution is advised in patients with known hypersensitivity to pancreatic enzymes or silicone compounds.